Christopher Lademacher

3.3k citations

35 papers · 2.3k indexed · 1 hit paper · h-index 23

Nephrology top 0.5%
Surgery top 5%
Infectious Diseases top 2%
Epidemiology top 5%
Rheumatology top 2%

Co-authors: Michael A. Becker H. Ralph Schumacher Patricia MacDonald Eric Lloyd Barbara Hunt Nancy Joseph‐Ridge Robert L. Wortmann Luis R. Espinoza
Topics: Antifungal resistance and susceptibility (16 papers)Pneumocystis jirovecii pneumonia detection and treatment (7 papers)Fungal Infections and Studies (6 papers)
Cited by: Nephrology Rheumatology Infectious Diseases
Journals: Gastroenterology The Journal of Clinical Endocrinology & Metabolism Clinical Infectious Diseases
Partner nations: United States United Kingdom Japan

In The Last Decade

Christopher Lademacher

35 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28‐week, phase III, randomized, double‐blind, parallel‐group trial

2008 482 citations H. Ralph Schumacher, Michael A. Becker et al. profile →

Peers

Countries citing papers authored by Christopher Lademacher

Since Specialization

Citations

This map shows the geographic impact of Christopher Lademacher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Lademacher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Lademacher more than expected).

Fields of papers citing papers by Christopher Lademacher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Lademacher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Lademacher. The network helps show where Christopher Lademacher may publish in the future.

Co-authorship network of co-authors of Christopher Lademacher

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Lademacher. A scholar is included among the top collaborators of Christopher Lademacher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Lademacher. Christopher Lademacher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial 2020 ·Arthritis Research & Therapy ·Tsutomu Takeuchi,Yoshiya Tanaka,(unknown),Yuichiro Kaneko,Masako Saitō,(unknown),Ronald Smulders,Christopher Lademacher	11
2	Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA) 2020 ·Menopause The Journal of The North American Menopause Society ·Nanette Santoro,Arthur Waldbaum,Samuel Lederman,Robin Kroll,Graeme L. Fraser,Christopher Lademacher,Laurence Skillern,James Young,Steven Ramael	44
3	Outcomes by MIC Values for Patients Treated with Isavuconazole or Voriconazole for Invasive Aspergillosis in the Phase 3 SECURE and VITAL Trials 2018 ·Antimicrobial Agents and Chemotherapy ·David R. Andes,Mahmoud A. Ghannoum,Pranab K. Mukherjee,Laura Kovanda,Qiaoyang Lu,Mark E. Jones,Anne Santerre Henriksen,Christopher Lademacher,William Hope	20
4	A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor 2018 ·American Journal of Transplantation ·Flavio Vincenti,Klemens Budde,Pierre Merville,Fuad S. Shihab,V. Ram Peddi,Malay B. Shah,Kate Wyburn,E. Cassuto‐Viguier,Alexander Weidemann,Misun Lee,(unknown),(unknown),Xuegong Wang,Christopher Lademacher	46
5	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial 2018 ·Mycoses ·John R. Perfect,Oliver A. Cornely,M. Heep,Luis Ostrosky‐Zeichner,Kathleen M. Mullane,Rochelle Maher,Rodney Croos‐Dabrera,Christopher Lademacher,Marc Engelhardt,(unknown),Francisco M. Marty	24
6	A Phase 3 Study of Micafungin Versus Amphotericin B Deoxycholate in Infants With Invasive Candidiasis 2018 ·The Pediatric Infectious Disease Journal ·Daniel K. Benjamin,David Kaufman,William Hope,P. Brian Smith,Antonio Arrieta,Paolo Manzoni,Laura Kovanda,Christopher Lademacher,(unknown),(unknown),Chunzhang Wu,Atsunori Kaibara,Thomas J. Walsh	27
7	Isavuconazole for treatment of rare invasive fungal diseases 2018 ·Mycoses ·Oliver A. Cornely,Kathleen M. Mullane,Luis Ostrosky‐Zeichner,Rochelle Maher,Rodney Croos‐Dabrera,Qiaoyang Lu,Christopher Lademacher,John R. Perfect,Ilana Oren,(unknown),Michael Giladi,Francisco M. Marty,Galia Rahav	34
8	Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population 2017 ·Therapeutic Advances in Gastroenterology ·Leticia Delgado‐Herrera,Kathryn Lasch,Bernhardt Zeiher,Anthony Lembo,Douglas A. Drossman,(unknown),Kathleen Rosa,Christopher Lademacher,Rob Arbuckle	4
9	QT Interval Shortening With Isavuconazole:In VitroandIn VivoEffects on Cardiac Repolarization 2017 ·Clinical Pharmacology & Therapeutics ·James J. Keirns,Amit Desai,Donna Kowalski,Christopher Lademacher,Salim Mujais,Barbara A. Parker,(unknown),Robert Townsend,(unknown),Takaharu Yamazaki,Mark Yen,(unknown)	59
10	Pharmacokinetic Interaction Between Isavuconazole and a Fixed‐Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects 2016 ·Clinical Pharmacology in Drug Development ·Takao Yamazaki,Amit Desai,David Han,Kota Kato,Donna Kowalski,Shahzad Akhtar,Christopher Lademacher,Laura Kovanda,Robert Townsend	23
11	No Dose Adjustment Necessary for Isavuconazole in Obese Patients 2016 ·Open Forum Infectious Diseases ·Amit Desai,Laura Kovanda,David R. Andes,Christopher Lademacher,Robert Townsend,Marc Engelhardt,Peter L. Bonate	1
12	Pharmacokinetic and Pharmacodynamic Evaluation of the Drug‐Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects 2016 ·Clinical Pharmacology in Drug Development ·Amit Desai,Takao Yamazaki,(unknown),Donna Kowalski,Christopher Lademacher,(unknown),Shahzad Akhtar,Robert Townsend	22
13	Pharmacokinetic Evaluation of CYP3A4‐Mediated Drug‐Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults 2016 ·Clinical Pharmacology in Drug Development ·Robert Townsend,(unknown),(unknown),Shahzad Akhtar,Donna Kowalski,Christopher Lademacher,Kenneth C. Lasseter,(unknown),(unknown),Anne Schmitt‐Hoffmann,Takao Yamazaki,Amit Desai	92
14	Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome 2014 ·Clinical and Translational Gastroenterology ·Patrick Marquis,Kathryn Lasch,Leticia Delgado‐Herrera,Smita Kothari,Anthony Lembo,Christopher Lademacher,(unknown),Akito Nishida,(unknown),Elisabeth Piault,Kathleen Rosa,Bernhardt Zeiher	14
15	The Irritable Bowel Syndrome-Diarrhea (IBS-D) Daily Symptom Diary and Event Log: A Newly Developed Patient-Reported Outcome (PRO) Measure 2011 ·Gastroenterology ·Kathryn Lasch,Leticia Delgado‐Herrera,Smita Kothari,Kathleen Rosa,Bernhardt Zeiher,Christopher Lademacher,(unknown),Akito Nishida,Patrick Marquis	2
16	Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non‐purine selective inhibitor of xanthine oxidase 2010 ·British Journal of Clinical Pharmacology ·Brian Grabowski,Reza Khosravan,Jingtao Wu,Laurent Vernillet,Christopher Lademacher	20
17	The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial 2010 ·Arthritis Research & Therapy ·Michael A. Becker,H. Ralph Schumacher,Luis R. Espinoza,Alvin F. Wells,Patricia MacDonald,Eric Lloyd,Christopher Lademacher	381
18	Clinical Efficacy and Safety of Successful Longterm Urate Lowering with Febuxostat or Allopurinol in Subjects with Gout 2009 ·The Journal of Rheumatology ·Michael A. Becker,H. Ralph Schumacher,Patricia MacDonald,Eric Lloyd,Christopher Lademacher	200
19	Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study 2008 ·Lara D. Veeken ·H. Ralph Schumacher,Michael A. Becker,Elisabeth A. Lloyd,Penny A. MacDonald,Christopher Lademacher	181
20	Determinants of the Clinical Outcomes of Gout During the First Year of Urate-Lowering Therapy 2008 ·Nucleosides Nucleotides & Nucleic Acids ·Michael A. Becker,Patricia MacDonald,Barbara Hunt,Christopher Lademacher,Nancy Joseph‐Ridge	73

About Christopher Lademacher

Christopher Lademacher is a scholar working on Infectious Diseases, Nephrology and Gastroenterology, having authored 35 papers that have together received 2.3k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (16 papers), Pneumocystis jirovecii pneumonia detection and treatment (7 papers) and Fungal Infections and Studies (6 papers). The work is most often cited by research in Nephrology (1.3k citations), Rheumatology (593 citations) and Infectious Diseases (645 citations). Christopher Lademacher has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Michael A. Becker, H. Ralph Schumacher, Patricia MacDonald, Eric Lloyd, Barbara Hunt, Nancy Joseph‐Ridge, Robert L. Wortmann, Luis R. Espinoza, Alvin F. Wells and Amit Desai. Their work appears in journals such as Gastroenterology, The Journal of Clinical Endocrinology & Metabolism and Clinical Infectious Diseases.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact